MedTrace Logo

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy

NCT02439541 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-03-16

No results posted yet for this study

Summary

Phase I-II Clinical Trial-Safety and efficacy of umbilical cord derived mesenchymal stem cells (UC-MSCs) in patients with chronic heart ischemia cohort and perspective study.

Conditions

Interventions

BIOLOGICAL

UCMSC group

Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10\^7)

Sponsors & Collaborators

  • Ivy Institute of Stem Cells Co. Ltd

    collaborator INDUSTRY

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Bing Liu, M.D · 307-IVY Translational Medicine Center

  • Xiaozhong Zhang, M.D · Department of cardiology,Affiliated Hospital to Academy of Military Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02439541 on ClinicalTrials.gov